Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
21.69
+1.00 (4.83%)
At close: May 13, 2026, 4:00 PM EDT
21.61
-0.08 (-0.37%)
After-hours: May 13, 2026, 5:14 PM EDT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company’s lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
| Name | Position |
|---|---|
| Dr. Bhaskar Chaudhuri Ph.D. | Co-Founder & Director Emeritus |
| Dr. Patrick E. Burnett M.D., Ph.D. | Executive VP & Chief Medical Officer |
| Mr. Douglas DiRuggiero DMSC | Advanced Practitioner |
| Mr. Jeff Kiekhofer | VP & Controller |
| Mr. Larry Todd Edwards | Executive VP & Chief Commercial Officer |
| Mr. Masaru Matsuda Esq., J.D. | Executive VP, Chief Legal Officer & Corporate Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-05-06 | 10-Q | arqt-20260331.htm |
| 2026-04-21 | S-8 | arcutiss-8xapril2026.htm |
| 2026-02-25 | S-8 | arcutiss-8xfebruary2026.htm |
| 2025-12-08 | 8-K | arqt-20251203.htm |
| 2025-10-28 | 10-Q | arqt-20250930.htm |
| 2025-08-06 | 10-Q | arqt-20250630.htm |
| 2025-06-17 | 8-K | arqt-20250612.htm |
| 2025-05-06 | 8-K | arqt-20250506.htm |
| 2025-05-06 | 10-Q | arqt-20250331.htm |
| 2025-04-29 | DEF 14A | arqt-20250429.htm |
| Mr. Todd Franklin Watanabe M.A. | President, CEO & Director |
| Ms. Bethany Dudek Ph.D. | Chief Technical Officer |
| Ms. Latha Vairavan | Senior VP & Chief Financial Officer |